Ronald Witteles, MD
Enriched profileProfessor of Medicine, Division of Cardiovascular Medicine · Stanford University School of Medicine
Ronald Witteles is Professor of Medicine, Division of Cardiovascular Medicine at Stanford University School of Medicine. OpenAlex indexes 320 publications with 14,726 citations (h-index 50); ClinicalTrials.gov lists 4 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Advanced Heart Failure and Transplant Cardiology profiles in the findmyKOL directory.
Data verified 18 Oct 2026
Overview
Updated 18 Oct 2026
Ronald Witteles, MD, is Professor of Medicine, Division of Cardiovascular Medicine at Stanford University School of Medicine. The public record shows 320 publications with 14,726 citations (h-index 50), centered on Amyloidosis: Diagnosis, Treatment, Outcomes, Cardiac tumors and thrombi, Heart Failure Treatment and Management. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 11 companies, 1 NIH-funded awards (2026–2026).
- Most recent indexed publication: 2026 · Amyloid
- Top research focus: Amyloidosis: Diagnosis, Treatment, Outcomes
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 9 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 123.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation
Sponsor: Ronald Witteles
- Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure
Sponsor: Stanford University
Industry payments
Updated 18 Oct 2026
11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20256 payments$13,849openpaymentsdata.cms.gov ↗
- Alnylam Pharmaceuticals Inc.Program year20257 payments$11,207openpaymentsdata.cms.gov ↗
- BridgeBio Pharma, Inc.Program year20253 payments$10,175openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
55.2%Beta blocker12.8%Carvedilol58%Metoprolol Succinate42%Part D≥76 patientsAldosterone antagonist (MRA)11.5%Spironolactone81%Eplerenone19%Part D≥97 patients+ 12 more classes in this area
Nervous system
21.3%Other nervous system drugs21.3%Vyndamax87%Vyndaqel13%Part D≥64 patientsMetabolism & gastrointestinal
12.1%SGLT2 inhibitor11.7%Jardiance86%Farxiga14%Part D≥94 patientsPotassium supplement0.4%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
1 NIH research award on record, funded 2026–2026 per NIH RePORTER. The latest:
- Identification of Druggable Targets for Cancer Therapy-Induced Cardiotoxicity
Stanford University
FY2026$770,603R01HL178528
Congress activity
Updated 18 Oct 2026
12 congress contributions (2008–2022) across ASCO, ASH per OpenAlex. The most recent:
- Healthcare Utilization Among Patients with Advanced Systemic Light Chain Amyloidosis
ASH Annual Meeting
ASH2022Co-author - Free Light-Chain Levels in Patients with Transthyretin Amyloid Cardiomyopathy in Attr-ACT
ASH Annual Meeting
ASH2021Co-author - Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival
ASH Annual Meeting
ASH2021Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis.
Circulation. Heart failure
Review2025 - Value of Artificial Intelligence for Enhancing Suspicion of Cardiac Amyloidosis Using Electrocardiography and Echocardiography: A Narrative Review.
Journal of the American Heart Association
Review2025
Most-cited works
by citation count (OpenAlex)- 01Tafamidis Treatment for Patients with Transthyretin Amyloid CardiomyopathyArticle2,845 citations2018
- 02
- 04
- 05
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/ronald-witteles-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
Editorial & leadership roles
journal and society appointments- Deputy Editor
JACC: CardioOncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗ - Member
Cardiovascular Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.stanford.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.stanford.edu ↗
- Clinical Excellence Award
Division of Cardiovascular Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.stanford.edu ↗ - Clinical Research Award
Division of Cardiovascular Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.stanford.edu ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.stanford.edu ↗
- Fellow
American College of Cardiology (FACC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗ - Fellow
American College of Physicians (FACP)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
Secondary affiliations
appointments beyond the home institution- Co-Director
Stanford Amyloid Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗ - Co-Director
Stanford Multidisciplinary Sarcoidosis Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗ - Program Director
Internal Medicine Residency Training Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
Media & interviews
press, podcasts and appearances- PeerView podcast appearance with Julie L. Rosenthal
MD, FACC: 'Hidden in Plain Sight: Recognizing and Referring Patients With Transthyretin Cardiac Amyloidosis in Internal Medicine'
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →castfox.net ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →jacccepaudio.acc.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cardionerds.podcast.show ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Glenn Chertow, MD
Stanford University School of Medicine
Paul Heidenreich, MD
Stanford University School of Medicine
Alan Schatzberg, MD
Stanford University School of Medicine
Maximilian Diehn, MD
Stanford University School of Medicine
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens